Esperion Therapeutics Inc. (ESPR)
Summary
Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger
Stockholders of Esperion Therapeutics NASDAQ: ESPR approved the company's merger agreement with Essence Parent and Essence MergerCo at a special meeting held virtually on July 8, 2026, according to remarks delivered during the meeting.
ESPR Stock Surges 44% in a Month: Here's What You Need to Know
Esperion shares jump nearly 44% in a month. The primary catalyst was Archimed's agreement to acquire the company in a deal valued at up to $1.1 billion, including milestone payments.
Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
Esperion Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 139 | $360.58 | $442.02 | $81.44 | 22.59% |
| BG Bart Gancher Intech Investment Management LLC | 62,620 | $101,203.26 | $199,131.6 | $97,928.34 | 96.76% |
 Anthony Scaramucci SkyBridge Capital II LLC | 3.93M | $10.77M | $12.5M | $1.73M | 16.06% |
 Point72 Asset Management LP Point72 Asset Management LP | 1.69M | $4.63M | $5.37M | $743,324.02 | 16.06% |
 Jeff Ameen Spire Wealth Management | 17,767 | $72,590.82 | $56,499.06 | -$16,091.76 | -22.17% |
Esperion Therapeutics Inc. (ESPR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Esperion Therapeutics Inc. ever had a stock split?
Esperion Therapeutics Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Sheldon L. Koenig CEO | NASDAQ (NMS) Exchange | 29664W105 CUSIP |
| US Country | 294 Employees | 13 Jul 2026 Last Dividend | - Last Split | 26 Jun 2013 IPO Date |
Overview
Esperion Therapeutics, Inc. is a pioneering pharmaceutical company specialized in the development and commercialization of innovative medicines designed to combat elevated levels of low-density lipoprotein cholesterol (LDL-C). Established in 2008 and rooted in Ann Arbor, Michigan, Esperion has established itself as a key player in addressing hyperlipidemia, a major risk factor for cardiovascular diseases. Through strategic license and collaboration agreements with global pharmaceutical powerhouses such as Daiichi Sankyo Co. Ltd, Otsuka Pharmaceutical Co., Ltd, and Daiichi Sankyo Europe GmbH, Esperion enhances its capabilities to bring its novel treatment options to a broader patient population worldwide.
Products and Services
- NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets
- NILEMDO
- NUSTENDI
These oral, once-daily, non-statin medicines are developed by Esperion for the treatment of primary hyperlipidemia in adults. They are particularly targeted at patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who need an additional reduction in LDL-C levels. By offering a non-statin alternative, these products provide a solution for patients who may not tolerate statin therapies well.
An innovative ATP Citrate Lyase (ACL) inhibitor, NILEMDO significantly lowers LDL-C and cardiovascular risk by impeding cholesterol biosynthesis and enhancing the up-regulation of LDL receptors. This product stands out for its direct action on cholesterol production pathways, offering a novel mechanism of action in the fight against hyperlipidemia.
A combination of bempedoic acid and ezetimibe, NUSTENDI is formulated to target elevated LDL-C. It offers a dual mechanism of action by not only inhibiting cholesterol biosynthesis (via bempedoic acid) but also reducing intestinal cholesterol absorption (via ezetimibe). This synergistic action makes NUSTENDI a potent option for patients requiring comprehensive LDL-C management.
